Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab monthly dosing for hypercholesterolaemia in high cardiovascular-risk Aboriginal adults
ACTRN12616000871448Phase 3Terminated
- Sponsor
- South Australian Health and Medical Research Institute
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in hypercholesterolemia comparing Alirocumab with Placebo (2 arms). Primary endpoint: Change in LDL cholesterol from week 4 to week 24. Started Dec 2017; status: terminated.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on ACTRN12616000871448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000871448.